Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody

BMC Research Notes

Yan Li¹  Qiuping Zhang³  Beifen Shen²  Ming Yu²  Jiannan Feng²  Ming Lv²  Chunxia Qiao²  Yi Hu² 

[1] Laboratory of Molecular Immunology, Institute of Basic Medical Sciences, P.O. Box 130(3), Taiping Road #27, Beijing, 100850, China;Laboratory of Molecular Immunology, Institute of Basic Medical Sciences, Beijing, 100850, China;Department of Immunology, School of Basic Medical Science, Wuhan University, Donghu Road #185, Wuchang, Wuhan, 430071, China

关键词: Translocation;    Single chain antibody;    HER2;   

Others  :  1166199
DOI  :  10.1186/1756-0500-5-336

 received in 2012-01-24, accepted in 2012-05-16,  发布年份 2012

【 摘 要 】

Background

HER2 plays a critical role in the pathogenesis of many cancers and is linked to poor prognosis or cancer metastases. Monoclonal antibodies, such as Herceptin against HER2-overexpressing cancers, have showed satisfactory clinical therapeutic effect. However, they have difficulty to surmount obstacles to enter cells or blood–brain barrier.

Results

In this study, a cell-penetrating peptide Arg9 was linked to the C-terminus of anti-HER2 single chain antibody (MIL5scFv). Flow cytometry, confocal microscopy and electron microscopy analysis all revealed that Arg9 peptide facilitated the penetration of MIL5scFv into HER2-negative cell line NIH3T3 and orientate in mitochondria. More interestingly, Western blot assay showed the potential enhanced bioactivity of MIL5scFv-Arg9 in HER2+ cell line SKOV3, indicating that Arg9 could help large molecules (e.g. antibody) to penetrate into cells and therefore enhance its anti-neoplastic function.

Conclusions

Our work represented an attractive by preliminary strategy to enhance the therapeutic effect of existing antibodies by entering cells easier, or more desirable, surmounting the physical barriers, especially in hard-to-reach cancers such as brain metastases cases.

【 授权许可】

   
2012 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
• [2]Vogel C, Cobleigh M, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
• [3]De LC, Palmer DB, Piccoli R, Ritter MA, D’Alessio G: A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 2002, 8:1710-1719.
• [4]Walrant A, Correia I, Jiao CY, Lequin O, Bent EH, Goasdoué N, Lacombe C, Chassaing G, Sagan S, Alves ID: Different membrane behaviour and cellular uptake of three basic arginine-rich peptides. Biochim Biophys Acta 2011, 1808:382-393.
• [5]Liu BR, Huang YW, Winiarz JG, Chiang HJ, Lee HJ: Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Biomaterials 2011, 32:3520-3537.
• [6]Fei L, Ren L, Zaro JL, Shen WC: The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. J Drug Target 2011, 19:675-680.
• [7]Brasseur R, Divita G: Happy birthday cell penetrating peptides: already 20 years. Biochim Biophys Acta 2010, 1798:2177-2181.
• [8]Morris MC, Deshayes S, Heitz F, Divita G: Cell penetrating peptides: from molecular mechanisms to therapeutics. Biology of the Cell 2008, 100:201-207.
• [9]Matjaz Z, Ulo L: Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 2005, 57:529-545.
• [10]Cellina CS, Hovav N, Shira K, Nadav L, Ahuva N, Razin E: A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 2003, 102:2506-2512.
• [11]Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB: The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000, 97:13003-13008.
• [12]He D, Yang H, Lin Q, Huang H: Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J Biochem Cell Biol 2005, 37:192-205.
• [13]Xue Q, Wen HW, Meng YL, et al.: Construction, expression and internalization study of human anti-HBsAg single chain antibody/EGFP fusion proteins containing Arg9. China Biotechnol 2006, 26:1-6.
• [14]Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y: Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002, 277:2437-2443.
• [15]Futaki S, Suzuki T, Ohashi W, et al.: Arginine-rich peptides An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001, 276:5836-5840.
• [16]Zaro JL, Shen WC: Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem Biophys Res Commun 2003, 307:241-247.
• [17]Galluzzi L, Larochette N, Zamzami N, Kroemer G: Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
• [18]Maiti KK, Lee WS, Takeuchi T, et al.: Guanidine-containing molecular transporters: sorbitol-based transporters show high intracellular selectivity toward mitochondria. Angew Chem Int Ed Engl 2007, 46:5880-5884.
• [19]Zhao K, Zhao GM, Wu D, et al.: Cell-permeable pepide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004, 279:34682-34690.
• [20]Horobin RW, Trapp S, Weissig V: Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. J Control Release 2007, 121:125-136.
• [21]Richard MN, Ulri BN, Dmitri B, Marie AP, James DM, Christopher CB: Biological effects of anti-ErbB2 signal chain antibody selected for internalizing function. Biochem Biophys Res Commun 2001, 28:274-278.
• [22]Nieder C, Pawiniski A, Dalhaug A: Presentation and outcome in cancer patients with extensive spread to the brain. BMC Res Notes 2009, 2:247. BioMed Central Full Text